In-house development and optimization of manufacturing processes with a phase appropriate analytical approach, tailor-made to meet your project needs.

cGMP production of bulk drug substance and intermediates using E.coli based fermentation, with scale-up capabilities for clinical and commercial uses.

Research grade pNDA capabilities with a full complement of analytical capabilities. cGMP manufacturing slots for pDNA are available for 2022.

BioCina meticulously maintains cell banks to support development and cGMP manufacturing needs. Our cGMP facility contains a dedicated suite for cell banking, incubation, and transfer.